NIFTY NEARLY ACHIEVES 7760 TARGET; 7900 IS THE IMMEDIATE HURDLE
WORLD MARKETS
US indices soared 2.1% on Friday on the back of a strong
jobs report and ECB President Mario Draghi maintaining a dovish stance in a
speech.
Nonfarm payrolls data showed the U.S. economy created
211,000 jobs and increase in wages for November, beating market expectations.
The number of jobs created in October and September were also revised higher.
The unemployment rate stood unchanged at 5%. This should help bolster the case
for the U.S. Federal Reserve to raise rates at its December meeting.
The U.S. trade deficit widened unexpectedly by 3.4% to
$43.9 billion in October as exports fell to a three-year low, suggesting that
strong dollar pressure on trade could again weigh on economic growth in the
fourth quarter.
European Central Bank President Mario Draghi said
quantitative easing was unlimited."There is no particular limit to how we
can deploy any of our tools," he said.
European markets, except a 0.1% rise in FTSE, lost upto
0.6%.
Nymex oil settled 2.7% lower at
$39.97 a barrel after OPEC left its production levels unchanged for the third
year in a row despite a global supply glut. Gold climbed $23 to $1084 an ounce.
For the week, Dow and Nasdaq gained
0.3% each and S & P 500 rose 0.1%. European markets however fell 2.2%-4.8%
with DAX leading the tally. Nymex oil fell 4.2% for the week.
AT HOME
After a gap down opening, benchmark indices saw a
rangebound but choppy trade through rest of the session and finally ended lower
by a percent, extending the losing streak to third straight day and closing at
the lowest level since 18th November. Sensex settled at 25638, down 249 points
while Nifty lost 82 points to finish at 7782. BSE mid-cap and small-cap inidces
lost 1.1% and 0.6% respectively. Except a 0.4% and 0.1% higher Healthcare and
Metal indices respectively, all the BSE sectoral indices ended in red with
Utilities and Power indices leading the tally, down 2% and 1.8% respectively.
Sun Pharma surged 4% after the company announced that it
has received approval from the US FDA for generic version of Gleevec, a drug
that treats a rare form of blood cancer.
For the week, Sensex and Nifty lost 1.9% and 2%
respectively, breaking the two-week winning streak.
FIIs net sold stocks, index futures and stock futures
worth Rs 1745 cr, 966 cr and 325 cr respectively. DIIs were net buyers to the
tune of Rs 1069 cr.
Rupee depreciated 4 paise to end at 66.695/$.
The committee, led by Chief Economic Advisor Arvind
Subramanian submitted its report on GST to Finance Minister. The committee decided to provide a range for
the GST rate for various products and services: from 12% to 40% (the higher
rate being applicable for select products such as luxury cars or tobacco
products, etc). However, the key revenue neutral rate suggested by the CEA
panel stood at 15-15.5%. The standard rate for GST stood at 17-18%, the rate at
which most products would likely be taxed. The panel excluded real estate,
electricity and alcohol and petroleum products while calculating the tax rate,
as some states have expressed reservations over giving up tax control on the
lucrative items but the CEA panel suggested these be brought under the GST
ambit soon.
OUTLOOK
Today morning Nikkei is up a percent and half, other Asian
markets are trading with modest gains and SGX Nifty is suggesting about 40
points higher opening for our market.
Readers would recall that last week, we had advised going
short below the immediate support of 7890 for the target of 7760, where the
trendline adjoining recent bottoms on the hourly chart was placed. The
benchmark, after breaking 7890 support on Thursday, plunged to 7775 on Friday
before closing at 7782, vindicating our view.
While the benchmark is set for a gap up opening, the bias
would continue to be negative until immediate hurdle on the hourly chart,
placed around 7900 is taken out.
7775, the bottom made on Friday, would now be the
immediate support below which 7714-7690 region, where multiple supports on the
daily chart are placed, would be the import support area to eye.
No comments:
Post a Comment